Cargando…
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance
OBJECTIVES: In subjects with transmitted thymidine analogue mutations (TAMs), boosted PIs (PI/b) are often chosen to overcome possible resistance to the NRTI backbone. However, data to guide treatment selection are limited. Our aim was to obtain firmer guidance for clinical practice using real-world...
Autores principales: | Geretti, Anna Maria, White, Ellen, Orkin, Chloe, Tostevin, Anna, Tilston, Peter, Chadwick, David, Leen, Clifford, Sabin, Caroline, Dunn, David T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376847/ https://www.ncbi.nlm.nih.gov/pubmed/30544247 http://dx.doi.org/10.1093/jac/dky468 |
Ejemplares similares
-
Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
por: Stirrup, Oliver T, et al.
Publicado: (2019) -
Thymidine Analogues for Tracking DNA Synthesis
por: Cavanagh, Brenton L., et al.
Publicado: (2011) -
Renal mitochondrial toxicity: effects of thymidine analogues and tenofovir disoproxil fumarate in African people living with HIV
por: Hunt, Matthew, et al.
Publicado: (2022) -
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
por: Iwuji, Collins C., et al.
Publicado: (2020) -
Use of thymidine analogues to indicate vascular perfusion in tumours
por: Begg, A C, et al.
Publicado: (2000)